TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19891687
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05% foam applied twice daily for up to 2 weeks on psoriatic skin
Study: 19891687
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05% foam applied once daily for up to 4 weeks on psoriatic skin
Study: 19891687
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05% foam applied once daily for 4 weeks on healthy skin
Study: 14687248
Drug: Amoxicillin 875
Normalized name: amoxicillin 875 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 875 mg plus clavulanic acid 125 mg b.i.d., clarithromycin 500 mg b.i.d., omeprazole 20 mg b.i.d. (ACCO)
Study: 9562690
Drug: Engerix-B (commercial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix-B (commercial vaccine)
Study: 2738328
Drug: Cefotetan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (2 gr single dose during operation)
Study: 23029946
Drug: Flupirtine maleate
Normalized name: flupirtine maleate
DrugBank: Flupirtine (DB06623)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine maleate 100 mg thrice daily
Study: 23029946
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol hydrochloride 50 mg thrice daily
Study: 20491044
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of bevacizumab (1.25 mg) 48 hours before surgery
Study: 20491044
Drug: No intravitreal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravitreal injection (control group)
Study: 16082697
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nebulized albuterol
Study: 16082697
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nebulized racemic epinephrine
Study: 10402146
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment response (week 2)
Study: 2304505
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of Edmonston-Zagreb vaccine
Study: 2304505
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose of Edmonston-Zagreb vaccine
Study: 2304505
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of Edmonston-Zagreb vaccine
Study: 2304505
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of Schwarz vaccine
Study: 2304505
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose of Schwarz vaccine
Study: 2304505
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of Schwarz vaccine
Study: 2304505
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of Schwarz vaccine in nine-month-olds
Study: 7202858
Drug: Myo-inositol tablets
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myo-inositol tablets
Study: 24252125
Drug: Patient-level intervention
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-level intervention (one-hour visit with a Prevention Practitioner providing a tailored 'prevention prescription')
Study: 19250820
Drug: Post-radiation ('maintenance')
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-radiation ('maintenance') chemotherapy
Study: 19250820
Drug: Pre-radiation ('sandwich')
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-radiation ('sandwich') chemotherapy
Study: 17503220
Drug: Supportive-expressive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive group therapy (SEGT)
Study: 1801560
Drug: Intravenous gamma-globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gamma-globulin (IVGG) at doses of 200 or 400 mg/kg X 5
Study: 1801560
Drug: Intravenous gamma-globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gamma-globulin (IVGG)
Study: 26381519
Drug: Intravenous rhAPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rhAPC (24 µg·kg(‐1)·h(‐1))
Study: 23085041
Drug: 14-week behavioral
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-week behavioral treatment
Study: 31425781
Drug: Mepolizumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab treatment
Study: 9017772
Drug: Ceftibuten (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten (400 mg)
Study: 9017772
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (500 mg)
Study: 9017772
Drug: Cefaclor (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (500 mg)
Study: 3531311
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg b.i.d. plus aspirin 650 mg q.i.d.
Study: 3531311
Drug: Placebo b.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo b.i.d. plus aspirin 650 mg q.i.d.
Study: 28481230
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g isomaltulose in 400 mL of water
Study: 28481230
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g isomaltulose in 400 mL of green tea
Study: 28481230
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g sucrose in 400 mL of water
Study: 16571280
Drug: Astragalus Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus Injection (AI) 20 ml in 250 ml of 5% glucose solution given through intravenous dripping
Study: 12775739
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa plus low-dose cytarabine (IFN+LDAC)
Study: 10367553
Drug: MDMA (1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (1.7 mg/kg, orally) in humans
Study: 10367553
Drug: MDMA (1.7,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (1.7, 5.4, and 17.0 mg/kg) in rats
Study: 8904739
Drug: Befloxatone 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befloxatone 2.5 mg
Study: 1653145
Drug: Controlled-release tablets
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release tablets (30 mg every 12 h)
Study: 1653145
Drug: Solution (15
Normalized name: carboxymethylcellulose sodium 0.5 % Ophthalmic Solution (15 mL) / mineral oil 42.5 % / petrolatum 57.3 % Ophthalmic Ointment (3.5 GM) Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution (15 mg every 6 h)
Study: 27434297
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg Nilotinib
Study: 27434297
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Nilotinib
Study: 17690742
Drug: FEXOFENADINE 180
Normalized name: fexofenadine 180 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEXOFENADINE 180 mg Film Tablet (Drogsan A.S., Ankara, Turkey)
Study: 17690742
Drug: Telfast 180
Normalized name: WORMWOOD 55.8 g in 60 mL TOPICAL LIQUID [Healfast]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telfast 180 mg Tablet (Aventis Pharma, Frankfurt am Main, Germany)
Study: 40893
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose norgestrel/ethinyl estradiol preparation (300 mcg norgestrel and 30 mcg ee)
Study: 29659183
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intravitreal aflibercept (IVT‐AFL) injection every 4 weeks (0.5q4)
Study: 29659183
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg IVT‐AFL every 4 weeks (2q4)
Study: 29659183
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg IVT‐AFL every 8 weeks (2q8)
Study: 29659183
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intravitreal ranibizumab every 4 weeks (0.5q4)
Study: 29659183
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (IVT‐AFL and ranibizumab)
Study: 18091548
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin G 10% (ivIgG) - 6 mL [600 mg]/kg on day 1 and 3 mL [300 mg]/kg on day 2
Study: 18091548
Drug: Placebo (albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (albumin 0.1%) - 6 mL [6 mg]/kg on day 1 and 3 mL [3 mg]/kg on day 2
Study: 18091548
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin G 10% (ivIgG)
Study: 16935946
Drug: Telephone administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone administered cognitive behaviour therapy (CBT)
Study: 21929831
Drug: Face to
Normalized name: NAIR FACE TOP CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face to face cognitive behaviour therapy (CBT)
Study: 12971668
Drug: Family-based directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based directly observed treatment (FDOT)
Study: 12971668
Drug: Standard supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard supervised but non-observed therapy (ST)
Study: 3302841
Drug: Trazodone hydrochloride
Normalized name: Trazodone Hydrochloride
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trazodone hydrochloride 150 mg/day
Study: 2190839
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg tamoxifen/day
Study: 2190839
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg tamoxifen/day and 600 IU kallikrein/day
Study: 31520695
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy followed by resectability assessment by the Expert Panel
Study: 23443875
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol (1,000 mg)
Study: 23443875
Drug: Intracutaneous sterile
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracutaneous sterile water injection
Study: 14679399
Drug: 3MU of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3MU of IFN-beta twice a day at intervals of 5 and 19 h (Group A)
Study: 14679399
Drug: 3MU of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3MU of IFN-beta twice a day at intervals of 10 and 14 h (Group B)
Study: 10655829
Drug: Sequential single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential single pumping regimen
Study: 2069370
Drug: Netilmicin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin (6 mg/kg/day) given once daily (qd)
Study: 2069370
Drug: Netilmicin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin (6 mg/kg/day) given thrice daily (tid)
Study: 6347782
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg three times a day for 4-6 weeks
Study: 25750093
Drug: Mud-bath therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud-bath therapy (MBT)
Study: 23403431
Drug: GSK1322322 (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1322322 (100, 200, 400, 800, 1500 mg; 800 mg with high-fat meal)
Study: 23403431
Drug: GSK1322322 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1322322 (800 mg with high-fat meal)
Study: 19754931
Drug: Proprietary melon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprietary melon juice concentrate (Extramel) 10 mg corresponding to 140 IU SOD per capsule, taken once daily for 4 weeks
Study: 19754931
Drug: Placebo, taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, taken once daily for 4 weeks
Study: 1389351
Drug: Rembrandt Lightening
Normalized name: Rembrandt
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rembrandt Lightening Gel and Whitening Toothpaste
Study: 3905327
Drug: Iso Mack
Normalized name: iso-sulfan blue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iso Mack Retard 20 mg
Study: 3905327
Drug: Isoket Retard
Normalized name: Isoket Retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoket Retard 20 mg
Study: 3905327
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release preparations
Study: 3905327
Drug: Isoket retard
Normalized name: Isoket Retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoket retard 20 mg
Study: 29670335
Drug: Fimasartan (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan (120 mg)
Study: 20150523
Drug: Rosuvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (20 mg)
Study: 29670335
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of fimasartan and rosuvastatin
Study: 25171881
Drug: Magnetic sphincter
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic sphincter augmentation (MSAD)
Study: 21192940
Drug: Oral progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral progesterone (150 mg BID) during the follicular phase
Study: 18492838
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of phytosterols and (n‐3) LCPUFA
Study: 16538000
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (INS group)
Study: 14618042
Drug: Intravenous esmolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esmolol for 24 hours post-CABG followed by oral beta-blocker
Study: 14618042
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral beta-blocker treatment
Study: 8325278
Drug: Oral flumazenil
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral flumazenil (30 or 100 mg)
Study: 3791364
Drug: tolciclate solution
Normalized name: tolciclate
DrugBank: Tolciclate (DB13360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolciclate solution
Study: 25946305
Drug: Light shoes
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light shoes (352 ± 18.4 g)
Study: 25946305
Drug: Heavy shoes
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy shoes (637 ± 17.7 g)
Study: 23911013
Drug: Dapagliflozin 2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 2.5, 5, or 10 mg/day
Study: 23631622
Drug: Psychiatric-Psychodynamic Treatment
Normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric-Psychodynamic Treatment
Study: 17064498
Drug: Thrombolytic agents
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic agents (urokinase or rt-PA) for massive and sub-massive PTE
Study: 17064498
Drug: Anticoagulant agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant agents (IV infusion of unfractioned heparin or subcutaneous low-molecular-weight heparin) for non-massive PTE
Study: 11036119
Drug: Troponin T
Normalized name: Troponin T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troponin T levels <0.06 microg/L
Study: 11036119
Drug: Troponin T
Normalized name: Troponin T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troponin T levels 0.06 to 0.59 microg/L
Study: 11036119
Drug: Troponin T
Normalized name: Troponin T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troponin T levels ≥0.60 microg/L
Study: 11036119
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein levels <2 mg/L
Study: 11036119
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein levels 2 to 10 mg/L
Study: 11036119
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein levels >10 mg/L
Study: 11036119
Drug: Fibrinogen levels
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen levels <3.4 g/L
Study: 11036119
Drug: Fibrinogen levels
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen levels 3.4 to 3.9 g/L
Study: 11036119
Drug: Fibrinogen levels
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen levels ≥4.0 g/L
Study: 7661066
Drug: Amiodarone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone treatment (800 mg/day for 2 weeks, then 400 mg/day thereafter)
Study: 2748528
Drug: Adinazolam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adinazolam (10 to 60 mg daily, divided doses)
Study: 862331
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of antidiuretic hormone at a low rate for 1 hr
Study: 862331
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of antidiuretic hormone
Study: 27353245
Drug: Extended-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release methylphenidate (Ritalin® LA at a dose of 0.6 mg/kg)
Study: 21145618
Drug: ABT‐874 (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐874 (dosage not specified)
Study: 18940114
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine 1 ml/kg with tramadol 1 mg/kg body weight
Study: 18940114
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine 1 ml/kg body weight
Study: 14584858
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy using an expanded polytetrafluoroethylene (ePTFE) membrane and demineralized freeze-dried bone allograft (DFDBA)
Study: 11103236
Drug: Sequential methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sequential methotrexate and 5‐fluorouracil
Study: 9058218
Drug: Intravenous milrinone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous milrinone, 50 micrograms/kg loading dose over 20 minutes followed by 0.5 microgram/kg/min infusion
Study: 9058218
Drug: Open-label milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label milrinone administered after initial failure to wean from bypass
Study: 8412049
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 6 mg
Study: 31377895
Drug: Vaginal laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal laser treatment (3 treatments administered 4 weeks apart)
Study: 29546832
Drug: TA‐65 (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA‐65 (16 mg daily for 12 weeks)
Study: 22431716
Drug: Imiquimod, 5%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod, 5%, cream 5 d/wk for 3 months
Study: 22431716
Drug: Imiquimod, 5%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod, 5%, cream 5 d/wk for 3 months plus tazarotene, 0.1%, gel 2 d/wk for 3 months
Study: 18577931
Drug: Nifedipine in
Normalized name: nifedipine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine in combination with haloperidol
Study: 15854633
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (400 mug)
Study: 11793395
Drug: Wa x
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wa x UK vaccine (P1A[8],G6); single oral dose;
Study: 11793395
Drug: Wa x
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wa x (DS-1 x UK) vaccine (P1A[8],G2); single oral dose;
Study: 10890259
Drug: Cefdinir 600
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir 600 mg QD
Study: 10890259
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 250 mg QID
Study: 7580360
Drug: Aprotinin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (2 million KIU IV at induction of anesthesia and 2 million KIU added to the extracorporeal circuit, followed by infusion of 500 thousand KIU/h during surgery)
Study: 7580360
Drug: Epsilon-aminocaproic acid
Normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epsilon-aminocaproic acid (10 g IV at induction of anesthesia, followed by infusion of 2 g/h for 5 hours)
Study: 7580360
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg/kg IV within 30 minutes after induction of anesthesia, followed by infusion of 1 mg/kg per hour for 10 hours)
Study: 7580360
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antifibrinolytic therapy)
Study: 6370748
Drug: 0.1% Ro
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% Ro 12‐7024 ointment
Study: 27213795
Drug: Gliatilin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliatilin (1000 mg/4ml, 12-15 doses intravenously, then 1 capsule b.i.d. for 4 months orally)
Study: 27213795
Drug: Standard neuroprotective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard neuroprotective therapy (not specified)